300009.SZ
300009.SZ
CNE100000GY2
ANKEBIO
Loading chart...

Company Profile

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, immunohistochemical, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostic kits. In addition, it offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care products, including anti-aging, masks, essential liquids, and mouthwash; and sybthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, the company provides autosomal, sex chromosome, and other kits; paternity testing, tumor biological immunotherapy technology, and DNA testing services. Additionally, the company offers monoclonal antibody drugs, such as Trastuzumab to treat patients with breast and gastric cancers under the ANTRASTUIN brand; Bevacizumab, an anti-VFDF product; ANKEBIO anti-PD1; and anti-covid19 products. The company was founded in 2000 and is based in Hefei, China.

Related stocks

9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
9969.HK
9969.HK • China
INNOCARE
12.73 HKD
2.87B USD 1Y -23.4%
1877.HK
1877.HK • China
JUNSHI BIO
17.65 HKD
2.31B USD 1Y -40.6%
688166.SS
688166.SS • China
BRIGHTGENE BIO-MEDICAL TECHNOLO
33.53 CNY
2.19B USD 1Y -41.8%
300255.SZ
300255.SZ • China
CHANGSHAN PHARMA
22.15 CNY
3.05B USD 1Y -55.1%
300204.SZ
300204.SZ • China
STAIDSON BIO
20.66 CNY
1.67B USD 1Y -38.7%
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
688105.SS
688105.SS • China
NANJING VAZYME BIOTECH CO LTD
26.6 CNY
2.06B USD 1Y +49.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
36.0% p.a.
Max Drawdown (5Y)
-46.7%
Sharpe Ratio (5Y)
-0.28
Beta Factor
0.37
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (36.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -60.3% in the extended horizon.
ende